Dose-ranging Study of Nemolizumab in Atopic Dermatitis

The aim of the study is to assess the efficacy of several subcutaneous doses of nemolizumab
in moderate-to-severe AD subjects with severe pruritus receiving topical corticosteroids, who
were not adequately controlled with topical treatments.

Inclusion Criteria:

- Male or female subjects ≥ 18 years (or legal age when higher)

- Chronic AD, that has been present for at least 2 years before the visit

- Eczema Area and Severity Index (EASI) score ≥12

- IGA score ≥ 3

- AD involvement ≥ 10% of Body Surface Area (BSA)

- Severe pruritus on at least 3 of the last 7 days before the visit

- Documented recent history (within 6 months before the visit) of inadequate response to
topical medications

- Female subjects must fulfill one of the criteria below:

- Female subjects of non-childbearing potential

- Female subjects of childbearing potential who agree to a true abstinence or to
use an effective or highly effective method of contraception throughout the
clinical trial and for 120 days after the last study drug administration

Exclusion Criteria:

- Body weight < 45 kg

- subjects with a medical history of asthma requiring hospitalization in the last 12
months before screening visit and/or whose asthma has not been well-controlled during
the last 3 months before the screening visit and/or Peak Expiratory Flow (PEF) <80% of
the predicted value

- Cutaneous bacterial or viral infection within 1 week before the screening visit or
during the run-in period

- Infection requiring treatment with oral or parenteral antibiotics, antivirals,
antiparasitics or antifungals within 1 week before the screening visit or during the
run-in period

- History of intolerance to low or mid potency TCS or for whom TCS is not advisable